Objective:

To estimate the association between the timing of antidiabetic medication (ADM) initiation and the risk of major adverse cardiovascular events (MACE) and all-cause mortality among individuals with newly diagnosed type 2 diabetes (T2D).

Approach:

• Study Design: A retrospective cohort study using a clone-censor-weight approach, linking the Kangbuk Samsung Health Study cohort with Korea’s National Health Insurance claims database from 2013 to 2022.
• Cohort Selection: Included adults aged ≥18 years with prediabetes and newly diagnosed T2D, defined by HbA1c ≥6.5% or FPG ≥126 mg/dL.
• Treatment Strategies: Four treatment strategies based on ADM initiation timing: within 3 months, within 6 months, within 12 months, and no initiation within 12 months.
• Outcome Measures: Primary outcome was a composite of modified 3-point MACE (myocardial infarction, stroke, and all-cause mortality) and all-cause mortality as a separate coprimary outcome.
• Statistical Analysis: Utilized pooled logistic regression models and time-varying inverse probability of censoring weights to adjust for selection bias. The analysis also accounted for confounding variables such as age, sex, body mass index, and comorbidities to ensure robust results.

Key Findings:

• Intensive glycemic control in early diabetes is associated with reduced MACE and mortality.
• The legacy effect from early glycemic control persists even after later deterioration.
• Evidence on the specific timing of ADM initiation and its impact on cardiovascular outcomes is limited.

Interpretation:

The study clarifies the relationship between the timing of ADM initiation and cardiovascular outcomes in T2D.

Limitations:

• Potential selection biases due to observational study design.
• Censoring may introduce bias if driven by baseline and postbaseline prognostic factors.
• Lack of cause of death data limits the ability to define cardiovascular death.

Conclusion:

The findings suggest that earlier initiation of antidiabetic medications is associated with a lower risk of major adverse cardiovascular events and all-cause mortality in patients with newly diagnosed type 2 diabetes, highlighting the importance of timely treatment in improving long-term health outcomes.

Sources:

• Kangbuk Samsung Health Study